Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Clopidogrel bisulfate
170
CHF
CHF 170.00
In stock
CDX-D0505-M250250 mgCHF 170.00
| Product Details | |
|---|---|
| Synonyms | Clopidogrel bisulfate; Clopidogrel Hemisulfate; SR 25990C; (S)-Methyl (2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate hydrogensulfate |
| Product Type | Chemical |
| Properties | |
| Formula | C16H16ClNO2S . H2SO4 |
| MW | 321.8 . 98.1 |
| CAS | 120202-66-6 |
| RTECS | XJ9088269 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white powder. |
| Solubility | Soluble in DMSO (>30mg/ml), methanol or water (>30mg/ml). Insoluble in ether. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | FDEODCTUSIWGLK-UHFFFAOYSA-N |
| Smiles | ClC1=CC=CC=C1[C@H]([NH+]2CCC(SC=C3)=C3C2)C(OC)=O.[O-]S(=O)(O)=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
(S)-(+)-Clopidogrel is a prodrug that is metabolized by cytochrome P450 isoforms to produce an active metabolite, which is a selective, irreversible high-affinity antagonist of the platelet purinergic P2Y12 receptor. Potent antithrombotic antiplatelet agent. By inhibiting the Purinoceptor P2Y12 subtype it consequently inhibits ADP-induced platelet aggregation. (S)-(+)-Clopidogrel hydrogen sulfate is the active isomer. Compound can be used as analytical reference material.
Product References
(1) D.C.B. Mills, et al.; Arterioscler. Thromb. 12, 430 (1992) | (2) G. Feuerstein, et al.; Exp. Opin. Invest. Drugs 4, 425 (1995) | (3) P. Savi, et al.; BBRC 283, 379 (2001) | (4) P. Savi & J.M. Herbert; Semin. Thromb. Haemostas. 31, 174 (2005) | (5) I. von Kugelgen; Pharmacol.Ther. 110, 415 (2006) | (6) N. Ferri, et al.; Drugs 73, 1681 (2013)